1326PD - HIV1-positive men who have sex with men (HIV1-MSM) knowledge and attitudes towards anal cancer screening: A cross-sectional study

Date 08 October 2016
Event ESMO 2016 Congress
Session Public health and health economics
Topics Anal Cancer
Aetiology, Epidemiology, Screening and Prevention
Basic Scientific Principles
Presenter Alexis Vanhaesebrouck
Citation Annals of Oncology (2016) 27 (6): 462-468. 10.1093/annonc/mdw385
Authors A. Vanhaesebrouck1, S. Pernot2, J. Pavie3, M.L. Lucas3, L. Collias3, H. Péré4, J. Taieb5, S. Grabar1, L. Weiss3
  • 1Biostatistics And Epidemiology Unit, Groupe hospitalier Hôtel Dieu (AP-HP), 75004 - Paris/FR
  • 2Gastrointestinal Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 3Immunology, Hopital European George Pompidou, 75015 - Paris/FR
  • 4Biology, Hopital European George Pompidou, 75015 - Paris/FR
  • 5Gastroenterology And Digestive Oncology, Hopital European George Pompidou, 75015 - Paris/FR



Despite combined antiretroviral therapy, risk of anal cancer is eighty times higher in HIV1-MSM than in general population. Although no international consensus exist for routine screening of anal cancer for HIV1-MSM, guidelines in most western countries include at least digital examination and suggest that anal Pap test may be beneficial to diagnose high grade squamous intraepithelial lesion. This monocentric cross-sectional study aims to describe HIV1-MSM knowledge and attitudes towards anal cancer screening (ACS).


All adult patients (pts) HIV1-MSM who went to the Hôpital Européen Georges Pompidou in Paris (France) for a consultation were invited to complete a self-administered questionnaire about their knowledge regarding ACS and their previous experience. We explored factors associated with previous screening uptake, among patients familiar with ACS, with multivariable logistic regression.


Among an active list comprising 1019 pts HIV1-MSM, 410 completed the questionnaire between June 2015 and January 2016. Median age was 50 years (iqr, 42.5-57.5) and median time from HIV diagnosis was 14.2 years (iqr, 6.9-23.1). HIV viral load was 


Although 82% of the HIV1-MSM were familiar with ACS, only 57% of them have already taken a screening test. Information by physician seems the best intervention to promote the screening. Encouraging physicians to inform HIV1-MSM pts on anal cancer may improve ACS uptake. Moreover, more detailed information and better accessibility of screening centers should help improve screening rate.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.